If the two sides do reach an agreement, the titanic transaction could be among the biggest in Boston Scientific's history.

Cardiovascular Associates of America and Novocardia have joined forces to form what they describe as the "strongest cardiovascular network in America."

After high-risk medical devices go through the initial FDA approval process, it is relatively easy for manufacturers to get updates to those devices approved. New evidence suggests that this policy could be leading to more recalls, especially among cardiovascular devices.  

“Companies are undergoing a significant amount of change as they respond to economic challenges, higher costs and talent management issues,” says Andrew Challenger, SVP of Challenger, Gray & Christmas.